HBM HOLDINGS-B(02142) signs global strategic cooperation and licensing agreement with Bayer Pharmaceutical Company.

HBM Holdings-B (02142) announced that on December 17, 2025, the company has entered into a long-term global strategic partnership and licensing agreement with Roche, aimed at discovering and developing a new generation of multispecific antibodies. According to the agreement, HBM Holdings-B will collaborate with Roche to advance and accelerate the discovery of multispecific antibodies. In return, HBM Holdings-B will receive a total payment of $90 million. If Roche chooses to advance all potential projects, the company may also receive up to $1.035 billion in development and commercial milestone payments, as well as tiered royalties.